CO2020001471A2 - Compuesto pentacíclico - Google Patents

Compuesto pentacíclico

Info

Publication number
CO2020001471A2
CO2020001471A2 CONC2020/0001471A CO2020001471A CO2020001471A2 CO 2020001471 A2 CO2020001471 A2 CO 2020001471A2 CO 2020001471 A CO2020001471 A CO 2020001471A CO 2020001471 A2 CO2020001471 A2 CO 2020001471A2
Authority
CO
Colombia
Prior art keywords
pentacyclic compound
pentacyclic
compound
formulas
pharmaceutically acceptable
Prior art date
Application number
CONC2020/0001471A
Other languages
English (en)
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of CO2020001471A2 publication Critical patent/CO2020001471A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA COMPUESTOS REPRESENTADOS POR LAS FÓRMULAS (I) A (VI) O SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS.
CONC2020/0001471A 2017-09-07 2020-02-11 Compuesto pentacíclico CO2020001471A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017172169 2017-09-07
PCT/JP2018/032797 WO2019049869A1 (ja) 2017-09-07 2018-09-05 五環式化合物

Publications (1)

Publication Number Publication Date
CO2020001471A2 true CO2020001471A2 (es) 2020-05-29

Family

ID=65517037

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0001471A CO2020001471A2 (es) 2017-09-07 2020-02-11 Compuesto pentacíclico

Country Status (33)

Country Link
US (1) US10239889B1 (es)
EP (1) EP3680243B1 (es)
JP (1) JP6557441B1 (es)
KR (1) KR102307738B1 (es)
CN (1) CN111051316B (es)
AR (1) AR112788A1 (es)
AU (1) AU2018330578B2 (es)
BR (1) BR112020003197A2 (es)
CA (1) CA3072740A1 (es)
CL (1) CL2020000376A1 (es)
CO (1) CO2020001471A2 (es)
CY (1) CY1125355T1 (es)
DK (1) DK3680243T3 (es)
ES (1) ES2903172T3 (es)
HR (1) HRP20220019T1 (es)
HU (1) HUE056791T2 (es)
IL (1) IL272652B (es)
JO (1) JOP20200030A1 (es)
LT (1) LT3680243T (es)
MA (1) MA50093B1 (es)
MD (1) MD3680243T2 (es)
MX (1) MX2020001786A (es)
PH (1) PH12020500341A1 (es)
PL (1) PL3680243T3 (es)
PT (1) PT3680243T (es)
RS (1) RS62796B1 (es)
RU (1) RU2754557C1 (es)
SG (1) SG11202001240XA (es)
SI (1) SI3680243T1 (es)
TW (1) TWI707859B (es)
UA (1) UA125940C2 (es)
WO (1) WO2019049869A1 (es)
ZA (1) ZA202000970B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109467538A (zh) 2017-09-07 2019-03-15 和记黄埔医药(上海)有限公司 环烯烃取代的杂芳环类化合物及其用途
CN111093663A (zh) 2017-09-07 2020-05-01 奥古斯塔大学研究所公司 特异性akt3激活剂及其用途
JP7504864B2 (ja) * 2019-03-05 2024-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 五環式複素環化合物
AU2020233452A1 (en) * 2019-03-05 2021-09-02 Eisai R&D Management Co., Ltd. Salt of pentacyclic compound and crystals thereof
EP4069369A4 (en) * 2019-12-06 2024-02-14 Schrödinger, Inc. CYCLIC COMPOUNDS AND METHODS OF USE THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4187306A (en) * 1977-07-26 1980-02-05 Bayer Aktiengesellschaft Benzodiazepine-diones, a process for their production and their use as medicaments
DD258234A1 (de) * 1987-03-05 1988-07-13 Univ Leipzig Verfahren zur herstellung von pyrido/3',2':4,5/thieno/2,3-e/imidazo-/1,2-c/pyrimidinen sowie strukturanaloger -pyrimido/1,2-c/pyrimidine bzw. -1,3-diazepino/1,2-c/pyrimidine
RU2117670C1 (ru) * 1988-10-31 1998-08-20 Эйсай Ко., Лтд. Производные триазоло[1,4]диазепина и способы их получения
TW197442B (es) * 1990-02-08 1993-01-01 Pfizer
KR100203456B1 (ko) * 1995-06-20 1999-06-15 한승수 디하이드로에보디아민-에이치씨1를 유효성분으로 함유하는 알츠하이머병에 의한 치매 치료제
FR2779652B1 (fr) * 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
MX2007004640A (es) * 2004-10-20 2007-06-08 Hoffmann La Roche Derivados de benzodiazepina sustituidos con halogeno.
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
US8192080B2 (en) 2007-01-23 2012-06-05 Tsi Technologies Llc Microwire-controlled autoclave and method

Also Published As

Publication number Publication date
MA50093B1 (fr) 2022-05-31
EP3680243B1 (en) 2021-10-27
IL272652A (en) 2020-03-31
CL2020000376A1 (es) 2020-08-28
TW201920195A (zh) 2019-06-01
AR112788A1 (es) 2019-12-11
PH12020500341A1 (en) 2020-10-05
BR112020003197A2 (pt) 2020-09-29
HUE056791T2 (hu) 2022-03-28
AU2018330578A1 (en) 2020-02-27
MA50093A (fr) 2021-05-05
KR102307738B1 (ko) 2021-10-05
PL3680243T3 (pl) 2022-02-14
SI3680243T1 (sl) 2022-01-31
DK3680243T3 (da) 2022-01-10
EP3680243A4 (en) 2021-01-06
KR20200051585A (ko) 2020-05-13
TWI707859B (zh) 2020-10-21
MX2020001786A (es) 2022-09-13
AU2018330578B2 (en) 2022-11-10
JPWO2019049869A1 (ja) 2019-11-07
CN111051316B (zh) 2022-05-31
ZA202000970B (en) 2021-07-28
JOP20200030A1 (ar) 2020-02-12
ES2903172T3 (es) 2022-03-31
IL272652B (en) 2022-09-01
JP6557441B1 (ja) 2019-08-07
CA3072740A1 (en) 2019-03-14
PT3680243T (pt) 2022-01-12
HRP20220019T1 (hr) 2022-04-01
MD3680243T2 (ro) 2022-05-31
US10239889B1 (en) 2019-03-26
EP3680243A1 (en) 2020-07-15
RS62796B1 (sr) 2022-02-28
RU2754557C1 (ru) 2021-09-03
CN111051316A (zh) 2020-04-21
CY1125355T1 (el) 2024-02-16
WO2019049869A1 (ja) 2019-03-14
SG11202001240XA (en) 2020-03-30
US20190071452A1 (en) 2019-03-07
LT3680243T (lt) 2021-11-25
UA125940C2 (uk) 2022-07-13

Similar Documents

Publication Publication Date Title
CL2020000376A1 (es) Compuesto pentacíclico.
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
EA201792021A1 (ru) Ингибитор jak
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
CR20170315A (es) Inhibridores bace 1 selectivos
CL2018001067A1 (es) Compuesto piranodipiridínico.
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
MX2017016030A (es) Derivado de dihidropirrolopirazol sustituido.
EA201991241A1 (ru) Способ получения метоксиметилпиридин дикарбоксилата
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
BR112018006005A2 (pt) composto bicíclico e uso do mesmo para inibição de suv39h2
EA201792109A1 (ru) Конденсированные с тетрагидрофураном производные аминогидротиазина, пригодные для лечения болезни альцгеймера
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
BR112019002828A2 (pt) método de preparação de derivados de estireno substituído
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
EA201690908A1 (ru) Пиразолопиримидиновые соединения
EA201791596A1 (ru) Пиразоловые соединения
AR125853A2 (es) Composición farmacéutica de una sal hemisulfato de un compuesto nucleotídico
MX2018011117A (es) Forma cristalina.
UA107468U (uk) 25,27-ди-(5-тіо-октилокси)калікс[4]арен-краун-6